Home / Library / Advanced DHA

Advanced DHA

Composition: 650 mg DHA + 200 mg EPA (triglyceride-form fish oil)

Recommended tests

hs-CRP & Omega-3:Omega-6 Ratio

Advanced DHA is DHA-dominant (650 mg DHA to 200 mg EPA per serving) — the opposite ratio of many "heart health" fish oils, which tend to be EPA-heavy. DHA is a major structural fat in cell membranes, especially in the brain and retina, and both DHA and EPA compete with inflammatory omega-6 fatty acids for the same metabolic pathways.

Interpret alongside the whole picture — a low omega-3:omega-6 ratio combined with elevated hs-CRP is often used together here as a signal of overall inflammatory burden, not two unrelated numbers.

Composition & typical benefits

DHA-dominant, triglyceride-form fish oil

Triglyceride form — the form omega-3s naturally occur in, generally considered better absorbed than the synthetic ethyl-ester form used in some cheaper products
DHA-heavy formulation, positioned for brain, retina, and nerve support specifically, rather than as a general-purpose EPA-dominant anti-inflammatory oil
Natural preservatives (rosemary, mixed tocopherols) to reduce the "fish burp" issue that limits compliance with some fish oil products

Research noteA meta-analysis of 68 RCTs (4,601 people) found EPA and DHA supplementation significantly reduced CRP, IL-6, and TNF-alpha. A head-to-head network meta-analysis comparing DHA directly against EPA found the two had statistically similar effects on CRP, IL-6, and TNF-alpha — meaning DHA-dominant products like this one appear roughly as effective for inflammation as EPA-dominant ones, despite the different branding/positioning. DHA specifically also showed a significant reduction in diastolic blood pressure in people with dyslipidemia in a separate meta-analysis.

What the research says

Evidence by outcome

Outcome	Approx. evidence base	Typical finding
hs-CRP, IL-6, TNF-alpha (combined EPA+DHA)	Meta-analysis, 68 RCTs (4,601 people)	Significant reductions across all three inflammatory markers
DHA vs. EPA head-to-head for inflammation	Network meta-analysis	Statistically similar effects — DHA-dominant products appear roughly as effective as EPA-dominant ones for these markers
Diastolic blood pressure	Meta-analysis, people with dyslipidemia	DHA specifically showed a significant reduction (~3.1 mmHg)
Hard cardiovascular outcomes (events, mortality)	Large outcome trials (VITAL, STRENGTH, others)	Mixed — general-population primary-prevention trials have mostly been neutral; one high-dose, EPA-only prescription product (not this DHA-dominant formula) showed benefit in a different trial

The inflammation-marker evidence here is genuinely solid and among the better-supported findings in this library. Where it gets more nuanced is hard outcomes: large trials testing omega-3 supplementation for actually preventing heart attacks and strokes in the general population have mostly come back neutral, even though the lab-marker effects (CRP, triglycerides, blood pressure) are real. This is a similar pattern to Niacin and Homocysteine — reliable marker improvement, less certain translation to hard outcomes in unselected populations.

As with those other markers, this wasn't used as a standalone intervention in the neutral outcome trials — it's typically brought in alongside Berberine, Niacin, or other supplements addressing the same overlapping inflammatory/metabolic picture, rather than relied on by itself to move a hard outcome. A neutral result from testing it in isolation doesn't speak directly to how it's actually used in combination here.

Research summary chart

View PDF ↗

Dosages used in studies

What the research actually tested

Goal	Typical dose	Notes	Duration
Practitioner-used starting dose (this site)	960 mg combined (2 gelcaps, standard label serving)	Starting point for most people	Ongoing, per practitioner
Practitioner-used escalated dose	~1,920 mg combined (4 gelcaps)	Doubled when working to reduce hs-CRP more quickly	Ongoing, retest to guide dose
Inflammation, CRP (research range)	2,000–6,000 mg/day combined EPA+DHA	Higher EPA:DHA ratios showed more pronounced CRP reduction in this specific dose range	8–12+ weeks

Note: the research showing the strongest CRP reduction skewed toward higher EPA:DHA ratios than this DHA-dominant product — the doubled dose here still meaningfully increases total omega-3 intake, even though the EPA:DHA ratio itself stays the same as the label serving.

Safety notes & high-dose risks

What to watch for

Bleeding risk / blood thinner interaction: omega-3s have a mild blood-thinning effect — anyone on warfarin, other anticoagulants, or antiplatelet medication should coordinate with their prescribing provider, especially at higher doses.
Common side effects: "fish burps," mild GI upset — this product's rosemary/tocopherol preservative blend is specifically included to reduce that issue.
Fish/seafood allergy: sourced from fish oil — not appropriate for anyone with a fish allergy.
Generally well tolerated even at the higher research doses (2-6 g/day) used in inflammation trials, with GI upset being the main limiting factor rather than anything more serious.

Additional notes

Worth knowing

DHA-dominant vs. EPA-dominant — a real formulation choice, not just marketing: despite this product being positioned mainly for brain/eye health, the evidence suggests it's a reasonable choice for the hs-CRP/inflammation goal too, not just a cognitive-support-only product.
Why it's used alongside other supplements rather than alone: DHA is incorporated directly into cell membrane phospholipids, where it increases membrane fluidity. That fluidity plays a role in how well other nutrients and compounds transport across the membrane — this is part of the rationale for using it synergistically with other supplements addressing the same overlapping picture, rather than as a standalone intervention the way it was tested in the large outcome trials.
Ties to the omega-3:omega-6 ratio marker: if that ratio is being tracked alongside hs-CRP, this is one of the few supplements in this library addressing both at once.
Dose matters: the label serving (960 mg combined) is meaningfully lower than the 2-6 g/day range used in the inflammation research — worth a deliberate decision on serving count based on the specific goal, rather than assuming the label dose matches the research dose.
Retesting: hs-CRP and omega-3:omega-6 ratio roughly 8-12 weeks after starting or adjusting dose.

Shop on Fullscript Shop on Prodrome

Educational information only — not medical advice. Lab testing and any supplementation decisions should be made with a qualified healthcare provider who knows your personal health history. Research findings vary by population, dose, form, and study quality.

Some links go to Fullscript, where I may earn a commission at no extra cost to you. I only recommend supplements I've either used myself or seen work in my clients' lab data. Results vary from person to person.